Previous reports have demonstrated that the combination of Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD) botanical extracts, which are the components of an already approved cannabis-based medicine, reduce the Alzheimer-like phenotype of AβPP/PS1 transgenic mice when chronically administered during the early symptomatic stage. Here, we provide evidence that such natural cannabinoids are still effective in reducing memory impairment in AβPP/PS1 mice at advanced stages of the disease but are not effective in modifying the Aβ processing or in reducing the glial reactivity associated with aberrant Aβ deposition as occurs when administered at early stages of the disease. The present study also demonstrates that natural cannabinoids do not affect cognitive impairment associated with healthy aging in wild-type mice. The positive effects induced by Δ9-THC and CBD in aged AβPP/PS1 mice are associated with reduced GluR2/3 and increased levels of GABA-A Rα1 in cannabinoid-treated animals when compared with animals treated with vehicle alone.
CampbellVA, GowranA (2007) Alzheimer’s disease; taking the edge off with cannabinoids?Br J Pharmacol152, 655–662.
4.
KoppelJ, DaviesP (2008) Targeting the endocannabinoid system in Alzheimer’s disease. J Alzheimers Dis15, 495–504.
5.
AsoE, FerrerI (2014) Cannabinoids for treatment of Alzheimer’s disease: Moving toward the clinic. Front Pharmacol5, 37.
6.
BedseG, RomanoA, LavecchiaAM, CassanoT, GaetaniS (2015) The role of endocannabinoid signaling in the molecular mechanisms of neurodegeneration in Alzheimer’s disease. J Alzheimers Dis43, 1115–1136.
7.
LuHC, MackieK (2016) An introduction to the endogenous cannabinoid system. Biol Psychiatry79, 516–525.
8.
AsoE, PalomerE, JuvésS, MaldonadoR, MuñozFJ, FerrerI (2012) CB1 agonist ACEA protects neurons and reduces the cognitive impairment of AβPP/PS1 mice. J Alzheimers Dis30, 439–459.
WuJ, BieB, YangH, XuJJ, BrownDL, NaguibM (2013) Activation of the CB(2) receptor system reverses amyloid-induced memory deficiency. Neurobiol Aging34, 791–804.
12.
CasarejosMJ, PeruchoJ, GómezA, MuñozMP, Fernández-EstévezM, SagredoO, Fernández RuizJ, GuzmánM, de YébenesJG, MenaMA (2013) Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy. J Alzheimers Dis35, 525–539.
13.
AsoE, Sánchez-PlaA, Vegas-LozanoE, MaldonadoR, FerrerI (2015) Cannabis-based medicine reduces multiple pathological processes in AβPP/PS1 mice. J Alzheimers Dis43, 977–991.
14.
BorcheltDR, RatovitskiT, van LareJ, LeeMK, GonzalesV, JenkinsNA, CopelandNG, PriceDL, SisodiaSS (1997) Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron19, 939–945.
15.
Reagan-ShawS, NihalM, AhmadN (2008) Dose translation from animal to human studies revisited. FASEB J22, 659–661.
16.
ChengD, LowJK, LoggeW, GarnerB, KarlT (2014) Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe/PS1ΔE9 mice. Psychopharmacology (Berl)231, 3009–3017.
17.
ChengD, SpiroAS, JennerAM, GarnerB, KarlT (2014) Long-term cannabidiol treatment prevents the development of social recognition memory deficits in Alzheimer’s disease transgenic mice. J Alzheimers Dis42, 1383–1396.
18.
ChenR, ZhangJ, FanN, TengZQ, WuY, YangH, TangYP, SunH, SongY, ChenC (2013) Δ9-THC-caused synaptic and memory impairments are mediated through COX-2 signaling. Cell155, 1154–1165.
19.
MulderJ, ZilberterM, PasquareSJ, AlparA, SchulteG, FerreiraSG, KofalviA, Martín-MorenoAM, KeimpemaE, TanilaH, WatanabeM, MackieK, HortobagyiT, de CeballosML, HarkanyT (2011) Molecular reorganization of endocannabinoid signalling in Alzheimer’s disease. Brain134, 1041–1060.
20.
FaddaP, RobinsonL, FrattaW, PertweeRG, RiedelG (2004) Differential effects of THC- or CBD-rich cannabis extracts on working memory in rats. Neuropharmacology47, 1170–1179.
21.
HoffmanAF, LupicaCR (2013) Synaptic targets of Δ9-tetrahydrocannabinol in the central nervous system. Cold Spring Harb Perspect Med3, 8.
FerrerI, MartíE, TortosaA, BlasiJ (1998) Dystrophic neurites of senile plaques are defective in proteins involved in exocytosis and neurotransmission. J Neuropathol Exp Neurol57, 218–225.
24.
KellnerV, Menkes-CaspiN, BekerS, SternEA (2014) Amyloid-β alters ongoing neuronal activity and excitability in the frontal cortex. Neurobiol Aging35, 1982–1991.
25.
D’AmelioM, RossiniPM (2012) Brain excitability and connectivity of neuronal assemblies in Alzheimer’s disease: From animal models to human findings. Prog Neurobiol99, 42–60.
AlbayramO, AlferinkJ, PitschJ, PiyanovaA, NeitzertK, PoppensiekerK, MauerD, MichelK, LeglerA, BeckerA, MonoryK, LutzB, ZimmerA, Bilkei-GorzoA (2011) Role of CB1 cannabinoid receptors on GABAergic neurons in brain aging. Proc Natl Acad Sci U S A108, 11256–11261.
28.
ColizziM, McGuireP, PertweeRG, BhattacharyyaS (2016) Effect of cannabis on glutamate signalling in the brain, A systematic review of human and animal evidence. Neurosci Biobehav Rev64, 359–381.
29.
WadeDT, CollinC, StottC, DuncombeP (2010) Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult Scler16, 707–714.
